This observation aligns with findings from a recent study in AML, where PRMT1 was identified as a critical ferroptosis regulator and treatment with GSK3368715 enhanced ferroptosis sensitivity in vitro and in vivo [37]. The gene discussed is PRMT1; the disease is acute myeloid leukemia.